Original articles
-
Torin1 restores proliferation rate in Charcot-Marie- Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation
-
Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?
-
Emergencies cards for neuromuscular disorders 1st Consensus Meeting from UILDM – Italian Muscular Dystrophy Association Workshop report
-
Neuromuscular disorders and transition from pediatric to adult care in a multidisciplinary perspective: a narrative review of the scientific evidence and current debate
-
Gender effect on onset, prevalence and surgical treatment of cataract in patients with Myotonic Dystrophy type 1
-
Congenital myopathy associated with a novel mutation in MEGF10 gene, myofibrillar alteration and progressive course
-
Impact of the COVID-19 pandemic on neuromuscular rehabilitation setting. Part 2: patients and families’ views on the received health care during the pandemic
-
Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study
-
Peripheral circulation disturbances in two consecutive children with spinal muscular atrophy and literature review
-
The role of BAG3 in dilated cardiomyopathy and its association with Charcot-Marie-Tooth disease type 2
-
Ambulatory Duchenne muscular dystrophy children: cross-sectional correlation between function, quantitative muscle ultrasound and MRI
-
Xp21 contiguous gene deletion syndrome presenting as Duchenne muscular dystrophy and glycerol kinase deficiency associated with intellectual disability: case report and review literature
-
VCP-related myopathy: a case series and a review of literature
-
Telemedicine applied to neuromuscular disorders: focus on the COVID-19 pandemic era
-
Cardiac disorders worsen the final outcome in myasthenic crisis undergoing non-invasive mechanical ventilation: a retrospective 20-year study from a single center
-
Experience with telemedicine in neuromuscular clinic during COVID-19 pandemic
-
Frailties and critical issues in neuromuscular diseases highlighted by SARS-CoV-2 pandemic: how many patients are still “invisible”?